Cardiol Therapeutics Inc. (CRDL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
2265 Upper Middle Road East
Oakville, ON L6H 0G5
Canada
Phone
289 910 0850
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
18
First IPO Date
January 15, 2019
| Name | Title | Pay | Year Born |
| David G. Elsley | President, Chief Executive Officer & Director | 546,623 | N/A |
| Christopher J. Waddick | Chief Financial Officer, Corporate Secretary & Director | 214,301 | N/A |
| Bernard Lim | Chief Operating Officer | 375,027 | N/A |
| Andrew Warwick Hamer | Chief Medical Officer and Head of Research & Development | 565,866 | 1962 |
| Trevor Burns | Investor Relations | 0 | N/A |
| John A. Geddes BSCPT | Vice President of Corporate Development | 0 | N/A |
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.